Discovered differences in pancreatic cancer cells offer new hope for immunotherapy
最近審查：14.06.2024
所有iLive內容都經過醫學審查或事實檢查，以確保盡可能多的事實準確性。
我們有嚴格的採購指南，只鏈接到信譽良好的媒體網站，學術研究機構，並儘可能與醫學同行評審的研究相關聯。 請注意括號中的數字（[1]，[2]等）是這些研究的可點擊鏈接。
如果您認為我們的任何內容不准確，已過時或有疑問，請選擇它並按Ctrl + Enter。
A new study has found that pancreatic cancer cells vary depending on their location in the organ, providing new information about tumors and could lead to more targeted treatments.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer, and the number of diagnoses has increased significantly over the past decade. It is currently the seventh leading cause of cancer deaths among men and women worldwide and is expected to become the third leading cause of cancer-related deaths worldwide by 2030. This increase is due to several factors, such as an increase in the incidence of obesity and diabetes.
Houston Methodist's Chief of Gastrointestinal Medical Oncology, Dr. Maen Abdelrahim, pioneered and conceptualized the article entitled "Comparative Molecular Profiling of Head Versus Body and Tail Pancreatic Ductal Adenocarcinoma," published in npj Precision Oncology. The research team found that the anatomical location of the pancreatic tumor is an important factor influencing the results of systematic therapeutic interventions.
Abdelrahim and colleagues hypothesized that there is a difference in the microenvironment of tumors in the head of the pancreas compared to the body and tail, especially with regard to immune therapy receptors found in each of these parts pancreas.
"By focusing on the biology around the tumor and considering its location on the pancreas, we can better evaluate our treatment options," Abdelrahim said. "Rather than treating patients under the umbrella term of pancreatic malignancy, moving to a model based on tumor location could significantly change how clinicians develop preliminary treatment plans."
The team hopes this discovery will help clinicians develop more specific treatment plans and improve patient outcomes.